Clinical Investigator and Nursing Perspectives on the Management of Common Cancers

FACULTY INTERVIEWS
Noopur Raje, MD
Kena C Miller, ARNP

EDITOR
Neil Love, MD

MULTIPLE MYELOMA EDITION

Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/ONUMM114
Follow us at Facebook.com/ResearchToPractice  Follow us on Twitter @DrNeilLove
OVERVIEW OF ACTIVITY

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers and carries with it the worst death to new cases ratio (3 to 4). Patients with advanced active disease require immediate induction therapy to prepare eligible candidates for autologous stem cell transplant (ASCT). Optimal induction therapy for both ASCT candidates and those not eligible for transplant remains an area of clinical controversy, and multiple acceptable treatment options appear to merit consideration. Recent clinical research demonstrates an abundance of treatment options now available to patients with both newly diagnosed and relapsed or refractory MM. Published results from ongoing trials continually lead to the emergence of new therapeutic regimens and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with MM, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with MM. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with MM.

PURPOSE STATEMENT

To present the most current research developments in MM and to provide the perspectives of a clinical investigator and nurse practitioner on the diagnosis and treatment of MM.

LEARNING OBJECTIVES

- Evaluate the benefits and risks associated with systemic therapies used in the evidence-based treatment of MM, including chemotherapy regimens, proteasome inhibitors, corticosteroids and immunomodulatory drugs (IMiDs).
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
- Recognize the recent FDA approvals of carfilzomib and pomalidomide, and identify clinical situations in which these agents may be appropriate therapeutic options.
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with MM.

ACCREDITATION STATEMENT

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

This educational activity for 1.3 contact hours is provided by Research To Practice during the period of February 2014 through February 2015.

FOR SUCCESSFUL COMPLETION

This is an audio CNE program. This booklet contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/ONUMM114 also includes links to relevant abstracts and full-text articles.

To receive credit, participants should read the learning objectives and faculty disclosures, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/ONUMM114/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 75% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

If you would like to discontinue your complimentary subscription to Oncology Nursing Update, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
SELECT PUBLICATIONS

A randomized, multicenter, phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma. NCT01080391

A randomized, open-label phase 3 study of carfilzomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible patients with newly diagnosed multiple myeloma. NCT01818752


Leleu Y et al. Phase 2 multicenter, randomized, open-label study of 2 modalities of pomalidomide plus low-dose dexamethasone (POMD) in patients with multiple myeloma (MM), refractory to both lenalidomide and bortezomib (double refractory), IFM 2009-02. Haematologica 2011;96(S1); Abstract P148.

Lenalidomide/bortezomib/dexamethasone for multiple myeloma (MM) (RVD lite). NCT01782963


1. The following statement is true regarding pomalidomide for the treatment of MM.
   a. Pomalidomide has high potency and is generally well tolerated
   b. Pomalidomide was recently FDA approved in the relapsed/refractory setting
   c. Pomalidomide can cause embryo-fetal toxicity
   d. All of the above

2. Which of the following approaches is associated with a lower rate of peripheral neuropathy than the standard twice-weekly intravenous administration of bortezomib?
   a. Subcutaneous administration
   b. Weekly dosing schedule
   c. Both a and b

3. Bortezomib can be safely administered to patients with renal failure.
   a. True
   b. False

4. Recent studies have demonstrated that lenalidomide maintenance therapy after stem cell transplantation significantly improves progression-free survival compared to placebo for patients with MM.
   a. True
   b. False

5. Which of the following side effects is of concern when counseling patients with MM who are about to initiate treatment with lenalidomide?
   a. Rash
   b. Myelosuppression
   c. Thrombosis
   d. All of the above

6. Carfilzomib is associated with a lower incidence of peripheral neuropathy than that reported with bortezomib.
   a. True
   b. False

7. Which of the following is a common cause of renal failure — which may be reversible — in MM?
   a. Hypercalcemia
   b. Long-term use of nonsteroidal anti-inflammatory drugs
   c. Both a and b

8. The dose of dexamethasone can be safely reduced for elderly patients with MM.
   a. True
   b. False
PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

<table>
<thead>
<tr>
<th>4 = Excellent</th>
<th>3 = Good</th>
<th>2 = Adequate</th>
<th>1 = Suboptimal</th>
</tr>
</thead>
</table>

- Approaches to mitigate bortezomib-associated neuropathy with subcutaneous administration
  - BEFORE: 4 3 2 1
  - AFTER: 4 3 2 1

- Newly approved therapeutic options for patients with relapsed or refractory MM (eg, carfilzomib, pomalidomide)
  - BEFORE: 4 3 2 1
  - AFTER: 4 3 2 1

- Consideration of the “RVD lite” regimen for older patients
  - BEFORE: 4 3 2 1
  - AFTER: 4 3 2 1

- Counseling patients with MM who are about to begin maintenance therapy
  - BEFORE: 4 3 2 1
  - AFTER: 4 3 2 1

Has the activity unfairly influenced you toward a particular product or service?
- ☐ Yes
- ☐ No
If yes, please describe what was presented: ...........................................................................................................

Will this activity help you improve patient care?
- ☐ Yes
- ☐ No
- ☐ Not applicable
If yes, how will it help you improve patient care? .....................................................................................................

Did the activity meet your educational needs and expectations?
- ☐ Yes
- ☐ No
If no, please explain: ................................................................................................................................................

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

- 4 = Yes
- 3 = Will consider
- 2 = No
- 1 = Already doing
- N/M = LO not met
- N/A = Not applicable

As a result of this activity, I will be able to:
- Evaluate the benefits and risks associated with systemic therapies used in the evidence-based treatment of MM, including chemotherapy regimens, proteasome inhibitors, corticosteroids and immunomodulatory drugs (IMiDs). ... 4 3 2 1 N/M N/A
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment. ..................4 3 2 1 N/M N/A
- Recognize the recent FDA approvals of carfilzomib and pomalidomide, and identify clinical situations in which these agents may be appropriate therapeutic options. .................................................................4 3 2 1 N/M N/A
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with MM. ..................4 3 2 1 N/M N/A
What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and editor for this educational activity

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noopur Raje, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Kena C Miller, ARNP</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Editor

<table>
<thead>
<tr>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neil Love, MD</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

Other comments about the faculty and editor for this activity:

REQUEST FOR CREDIT — Please print clearly

Name:.......................................................... Specialty:..........................................................

Professional Designation:
☐ MD  ☐ DO  ☐ PharmD  ☐ NP  ☐ CNS  ☐ RN
☐ PA  ☐ Other..........................................................

Street Address:.......................................................... Box/Suite: ..........................................................

City, State, Zip:..........................................................

Telephone:.......................................................... Fax:..........................................................

Email:..........................................................

Signature:.......................................................... Date:..........................................................

The expiration date for this activity is February 2015. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ONUMM114/CNE.